Latest post

Professor Alan Stitt: Researching the AMD pathway

An interview with Alan Stitt about research in the AMD field.

science community

A strategic focus for Oxurion: researching and developing non-VEGF pathways

Jean Feyen, PhD., Chief Scientific Officer, and Andy De Deene, M.D., Global Head of Development, explain why Oxurion decided to focus on non-VEGF pathways.

back of the eye diseases, science community,

Research opportunities for treating age-related macular degeneration

Age-related macular degeneration (or AMD) is the leading cause of blindness. At Oxurion, we’re discovering new ways to treat both forms.